Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment

Targeting the immune checkpoint receptors cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed cell death 1 ligand 1 (PD-L1) represents a very attractive treatment modality for tumor patients. The administration of antibodies against these receptors can pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tunger, Antje, Kießler, Maximilian, Wehner, Rebekka, Temme, Achim, Meier, Friedegund, Bachmann, Michael, Schmitz, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874683/
https://www.ncbi.nlm.nih.gov/pubmed/29494517
http://dx.doi.org/10.3390/biomedicines6010026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874683/
https://www.ncbi.nlm.nih.gov/pubmed/29494517
http://dx.doi.org/10.3390/biomedicines6010026

Ejemplares similares